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toxicities. Due to the heterogeneity of fractions (fr) number 
we derived an 35 fr LQ equivalent DVH using different a/b: 4 
for prostate, 3 for rectum late toxicity, 4 for bladder late 
toxicity. 
Results: Clinical and therapeutic factors are shown in tab.1. 
At univariate analysis pT3b-T4 and SRT had worse bRFS (data 
confirmed at multivariate Cox regression analysis, p=0,019 
and 0,003); PSA > 10, GS >7 and pT3b-T4 were related to 
significant worse mRFS (only GS confirmed at multivariate 
analysis p=0,028). None variables resulted significant in terms 
of OS.Proctitis (CTCAE scale) occurred more frequently in pts 
treated with 3DCRT vs VMAT (p=0.001), urinary incontinence 
(CTCAE scale) were related to smaller bladder volume (p= 
0,008). Figure 1 shows the DVH comparison between 3D plans 
and VMAT-IGRT. 
Figure 1: DVH comparison between 3D plans and VMAT-IGRT. 
Above DVH represent mean volume for fixed doses. Below 
DVH represent mean dose for fixed volume. 
 
 
 
 
Conclusions: In this series, favorable clinical factors affected 
the survival outcomes and adjuvant radiotherapy seemed to 
have a better bRFS. Toxicity profile was very low and CTCAE 
scale resulted more reliable. PRODVH showed to be a useful 
and simple tool that has potentials to help in retrospective as 
well as in prospective study. Our current aim is to integrate 
PRODVH with the RTPacs in order to move from planning DVH 
to real time DVH as obtained by calculation with daily 
imaging. 
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Purpose/Objective: To quantify long term outcomes in 
patients above and below the age of 60 years treated with 
low dose rate (LDR) permanent prostate seed brachytherapy 
as monotherapy at single centre in the United Kingdom. 
Materials and Methods: Patients received trans-rectal 
ultrasound (TRUS) guided Iodine- 125 brachytherapy as 
monotherapy and were treated at our institution between 
March 1995 and September 2007. Using a pre-plan technique, 
145Gy was delivered to the prostate with a margin of 3mm. 
No patients received supplemental external beam 
radiotherapy. Neo-adjuvant hormonal therapy was only used 
for gland cytoreduction. Clinical staging was according to the 
1997 AJCC TNM system and patients were stratified using the 
Memorial Sloan-Kettering (MSK) model. Outcome data 
collected prospectively was stratified by age less than or 
greater than 60 years. This was analyzed in terms of overall 
survival, disease specific survival and PSA relapse-free 
survival (Nadir+2). Actuarial survival curves were calculated 
using the Kaplan-Meier method.  
 
 
Results: With a median follow up of 6.5 (range 0.2-17.7) 
years, 2157 patients were identified. Patient characteristics 
are shown in (table 1) with 575 (27%) patients treated being 
less than 60 and 1582 (73%) patients over the age of 60 years. 
A higher proportion of patients in the over 60 years cohort 
fell into MSK intermediate and high risk groups (48.8% vs. 
39%). The 10 years overall survival was higher in the <60 
cohort (86% vs. 75% Log Rank p<0.005). Stratified by age, 
death attributed to prostate cancer was 7.1% (n=41) in the 
<60 cohort and 15% (n=238) in the ≥60 cohort. At 10 years 
PSA relapse free survival was significantly higher in patients 
aged under 60 (77% vs. 70% p<0.05).  
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Conclusions: In this unscreened European population of men 
with low risk prostate cancer, outcomes were better in the 
under the age of 60 cohort. Younger age should not be 
considered a contraindication for brachytherapy as opposed 
to surgery  
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Purpose/Objective: Stereotactic Body Radiation Therapy 
(SBRT) is emerging as a promising modality treatment in the 
management of genitourinary malignancies. The delivery of 
very high radiation doses in few fractions with a steep dose 
gradient may improve the therapeutic ratio in the treatment 
of prostate cancer. In this phase II study we tested the 
efficacy and the impact on toxicity of SBRT in patients with 
low or intermediate risk prostate cancer. 
Materials and Methods: Patients with low or intermediate 
risk prostate cancer histologically confirmed were enrolled in 
this phase II study. The treatment schedule was 35 Gy in 5 
fractions on alternate days, delivered with RapidArc in FFF 
modality. Toxicity was defined according to CT-CAE criteria 
v3.0 and classified as acute if occurring within 90 days from 
treatment and as late after 90 days. Patient-reported quality 
of life (QOL) relative to urinary, sexual and gastrointestinal 
symptoms was evaluated through EPIC questionnaires. 
Results: Between January 2012 and March 2014 73 patients 
were enrolled (46 low risk, 27 intermediate risk). At a median 
follow up of 18 months (range 3-30 months) all patients 
experienced a complete biochemical response. Acute toxicity 
was mild; only 8 % of patients presented a rectal G2-toxicity, 
while a maximum G2-GU toxicity was recorded in 43% of 
patients, mainly represented by urgency, dysuria and 
stranguria. Regarding late toxicity, a G1 proctitis was 
recorded in 6% of patients and a G1-GU (urgency, cystitis) in 
31%; only 1 event of G2 urinary toxicity was observed 
(transient urethral stenosis). No heavier adverse events 
occurred. EPIC questionnaires revealed a slight worsening in 
the urinary domains during treatment, with a return to 
baseline three months after treatment. No significant 
modifications in any of the other domains explored were 
reported. 
Conclusions: Stereotactic Body Radiotherapy appears to be 
an effective therapeutic option in low and intermediate risk 
prostate cancer patients, associated with a good compliance 
and tolerance of the treatment modality, and a low profile of 
late toxicity.  
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Purpose/Objective: To determine the relationship between 
acute genitourinary (GU) toxicity and dose distributions of GU 
pelvic structures in patients who received focal dose-
escalation IMRT for localized prostate cancer. To develop a 
methodology of assessing planned dose to the bladder trigone 
using dose surface maps (DSM).  
Materials and Methods: 50 patients with intermediate/high 
risk localized prostate cancer underwent radiotherapy (RT) 
within a prospective study (DELINEATE, ISRCTN04483921) 
which involved image-guided IMRT of 74Gy/37# to the 
prostate and 82Gy/37# to the dominant intra-prostatic 
nodule. The whole bladder and catheterized urethra were 
prospectively delineated. A bladder trigone surrogate 
structure was retrospectively contoured as a triangle-shaped 
region between the transition of the urethra into the bladder 
wall caudally and the transition of the ureters in the bladder 
cranially. Axially, the posterior of the contour described the 
extent of the bladder trigone. The contour was expanded 
anteriorly from the bladder wall (Fig. 1 red contour). A copy 
of this structure was created and the contour enlarged 
anteriorly and laterally only (Fig. 1 green contour). DSM were 
generated for both structures using dosimetric analysis 
software, VODCA (MSS GmBH, Hagendorn, CH). A subtraction 
method was developed using MATLAB (Mathworks, Natwick, 
MA) to establish the dosimetric region of coincidence 
between the two DSMs, defining the bladder trigone surface 
(Fig. 1c). Cumulative dose surface histograms (DSH) were 
generated for bladder trigone (BT). In addition, whole 
bladder (WB) DSH and DVH for urethra were created in 
VODCA. 
